Ticker Launch
Sign inTry it free

SPAC · Deal announced

FutureTech II Acquisition Corp.

Business combination with Longevity Biomedical, Inc.

FutureTech II Acquisition Corp. is a blank-check company (SPAC) that raised $100M in its initial public offering on Feb 17, 2022, listing on Nasdaq Global Market. It agreed to combine with Longevity Biomedical, Inc., announced on Sep 16, 2024, at a stated value of $100M. The deal has not closed yet. Nelson Mullins advised the SPAC and Seward & Kissel advised the underwriters on the IPO.

Longevity Biomedical is a biopharmaceutical company advancing technologies across therapeutics, health monitoring and digital health solutions. Its aim is to restore tissue form and function in order to increase and improve health span.

Status
Deal announced
IPO date
Feb 17, 2022
IPO size
$100M
IPO exchange
Nasdaq Global Market
Target
Longevity Biomedical, Inc.
Target sector
Healthcare
Announced
Sep 16, 2024
Stated deal value
$100M
Combined company
Longevity Biomedical, Inc. (LBIO)
SPAC counsel (IPO)
Nelson Mullins
Underwriters' counsel (IPO)
Seward & Kissel

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers